Marc van Dijk

Marc van Dijk

Company: MiNK Therapeutics

Job title: CSO


Allogeneic iNKT cells – A Highly Scalable & Powerful Platform for Immunotherapy 11:30 am

Read more

day: Day Two

Developing In Vivo & In Vitro Models for iNKT-Based Cell Therapies & Checkpoint Combinations 3:00 pm

Developing adoptive transfer models for human and murine iNKT cells to demonstrate iNKT cell therapy proof-of-concept Generating models to assess the impact of checkpoint antibodies on iNKT cell therapy for future combinations Understanding the pros and cons of combination therapies, and MiNK Therapeutics’ future strategyRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.